TORONTO, Jan. 12, 2022 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), a pharmaceutical company
focused on central nervous system and cardiovascular markets,
announces that Gilbert Godin, Chief
Executive Officer, and Tim
Hendrickson, Chief Financial Officer, will present and host
one-on-one meetings with investors at the Sidoti Winter Virtual
Investor Conference, taking place January
19-20, 2022. The conference will be held in a virtual
meeting format.
HLS will present January 19, 2022,
at 1:00pm ET and the presentation can
be accessed live here:
https://sidoti.zoom.us/webinar/register/WN_aIn9_3_DT9-0JTKPV5dITA.
HLS will also host virtual one-on-ones with investors on Wednesday
and Thursday, January 19 and 20,
2022. To register for the presentation, visit
www.sidoti.com/events.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
ABOUT SIDOTI & COMPANY, LLC
For over two decades,
Sidoti has been a premier provider of independent securities
research focused specifically on Small Cap and Micro Cap companies
and the institutions that invest their securities, with most of our
coverage in the $50 million to
$3 billion market cap range.
Our approach affords companies and institutional clients a
combination of high-quality research, a Small Cap and Micro Cap
focused nationwide sales effort, and broad access to corporate
management teams. We serve 500+ institutional clients in the
U.S. and Canada, including many
leading managers with portfolios with $200
million to $2 billion of
AUM. Sidoti promotes meaningful interaction between issuers
and investors in the Small Cap and Micro Cap space through a series
of investor conferences (www.sidoti.com/events) we host each
year.
SOURCE HLS Therapeutics Inc.